Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00331773 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,116
- Enrollment target
NCT00331773 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 1,116 participants.
The verdict
NCT00331773, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,116 participants
- Enrollment target
Study Summary
RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving hypofractionated radiation therapy (higher doses over a shorter period of time), may be less costly with fewer side effects and just as effective in treating prostate cancer. PURPOSE: This randomized phase III trial is studying several different radiation therapy regimens to compare how well they work in treating patients with stage II prostate cancer.
Interventions
- RADIATION Conventional 3D-CRT or IMRT
- RADIATION Hypofractionated 3D-CRT or IMRT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,116 participants |
| Start Date | 2006-04 |
| Est. Completion | 2022-12-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00331773
The ClinicalTrials.gov registry entry for NCT00331773 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Conventional 3D-CRT or IMRT is the first listed.
NCT00331773 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00331773 about?
NCT00331773 is a clinical study titled "Radiation Therapy in Treating Patients With Stage II Prostate Cancer". RATIONALE: Giving radiation therapy that uses a 3-dimensional (3-D) image of the tumor to help focus thin beams of radiation directly on the tumor, and giving hypofractionated radiation therapy (higher doses over a shorter period of time), may be less costly with fewer side effects and just as effec...
What is the current status of trial NCT00331773?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,116 participants. The study started on 2006-04. Estimated completion is 2022-12-22.
What interventions are being tested in trial NCT00331773?
The interventions under investigation include: Conventional 3D-CRT or IMRT (RADIATION), Hypofractionated 3D-CRT or IMRT (RADIATION).
Who is sponsoring clinical trial NCT00331773?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.